Myristic acid

Myristic acid
Product Name Myristic acid
CAS No.: 544-63-8
Catalog No.: CFN93243
Molecular Formula: C14H28O2
Molecular Weight: 228.37 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Source: From Coconut oil
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Dietary myristic acid modifies the HDL-cholesterol concentration and liver scavenger receptor BI expression in the hamster. Myristic acid increases the activity of dihydroceramide Δ4-desaturase 1 through its N-terminal myristoylation, it also supports the immediate inhibitory effect of lauric acid on ruminal methanogens and methane release.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Pharm Biomed Res2023, 9(3):173-182.
  • Nutrients.2020, 12(12):3607.
  • Antiviral Res.2013, 98(3):386-93
  • Molecules.2021, 26(4):817.
  • J Food Drug Anal.2023, 31(2):254-277.
  • J Enzyme Inhib Med Chem.2019, 34(1):134-143
  • Toxins (Basel).2020, 12(4):210.
  • Food Chem.2019, 276:768-775
  • Molecules.2019, 24(7):E1290
  • J Nat Prod.2023, 86(2):264-275.
  • Kaempferol-3-O-galactoside

    Catalog No: CFN92079
    CAS No: 23627-87-4
    Price: $238/10mg
    Guaijaverin

    Catalog No: CFN98211
    CAS No: 22255-13-6
    Price: $138/20mg
    Kuwanon G

    Catalog No: CFN93278
    CAS No: 75629-19-5
    Price: $218/20mg
    Peonidin-3-O-glucoside chloride

    Catalog No: CFN92046
    CAS No: 6906-39-4
    Price: $318/5mg
    Sesamin

    Catalog No: CFN97034
    CAS No: 607-80-7
    Price: $40/20mg
    Anaerobe. 2004 Oct;10(5):269-76.
    Myristic acid supports the immediate inhibitory effect of lauric acid on ruminal methanogens and methane release.[Pubmed: 16701527]

    METHODS AND RESULTS:
    Two in vitro experiments were carried out with the Hohenheim gas test (HGT) apparatus in order to investigate dose-dependent effects and interactions of non-esterified lauric acid (C(12)) and Myristic acid (C(14)) given either individually or in mixture on ruminal methanogens and methanogenesis. Special emphasis was also put on the relationship between effects on methane formation and methanogenic counts. The in vitro incubations were conducted in 10mL ruminal fluid and 20mL buffer solution and lasted for 24h. In the first experiment, 14 levels of C(12), C(14) and stearic acid (C(18); control) were supplied each in increasing steps of 2.5mg covering the range from 0 to 32.5mg. In the second experiment, dosages ranging from 2.5 to 30mg C(12) were supplemented in steps of 2.5mg either without or with 10, 20 or 30mg of C(14). Counts of total Archaea and individual methanogenic orders were determined by the fluorescence in situ hybridization technique using 16S rRNA oligonucleotide probes. In experiment 1, a methane-suppressing effect of more than 80% was achieved with a supply of 30mg C(12), whereas C(14) and C(18) had no effect. Incubation liquid counts of total Archaea and individual methanogenic orders (Methanococcales, Methanosarcinales, Methanomicrobiales and Methanobacteriales) exponentially decreased as a response to C(12) and C(14) to about the same degree (up to 90%) and, to a lesser extent, by C(18). The proportions of the orders of total methanogenic population were not altered by any of the fatty acids. In experiment 2, an additional supply of 10 or 20mg of C(14) supported the suppression of methanogenesis and methanogens by C(12) synergistically. Supplementing 30mg instead of 20mg of C(14) did not further increase the efficacy of C(12) in suppressing methane formation and methanogens.
    CONCLUSIONS:
    The study illustrated the advantage of using mixtures of C(12) and C(14) in ruminant nutrition to suppress methane emission since mixtures will reduce the amounts of the less palatable C(12) required in feed.
    Biochimie, 2007, 89(12):1553-1561.
    Myristic acid increases the activity of dihydroceramide Δ4-desaturase 1 through its N-terminal myristoylation[Pubmed: 17716801]
    Dihydroceramide Δ4-desaturase (DES) catalyzes the desaturation of dihydroceramide into ceramide. In mammals, two gene isoforms named DES1 and DES2 have recently been identified. The regulation of these enzymes is still poorly understood. This study was designed to examine the possible N-myristoylation of DES1 and DES2 and the effect of this co-translational modification on dihydroceramide Δ4-desaturase activity.
    METHODS AND RESULTS:
    N-MyristoylTransferases (NMT) catalyze indeed the formation of a covalent linkage between myristoyl-CoA and the N-terminal glycine of candidate proteins, as found in the sequence of DES proteins. The expression of both rat DES in COS-7 cells evidenced first that DES1 but not DES2 was associated with an increased dihydroceramide Δ4-desaturase activity. Then, we showed that recombinant DES1 was myristoylated in vivo when expressed in COS-7 cells. In addition, in vitro myristoylation assay with a peptide substrate corresponding to the N-terminal sequence of the protein confirmed that NMT1 has a high affinity for DES1 myristoylation motif (apparent Km = 3.92 μM). Compared to an unmyristoylable mutant form of DES1 (Gly replaced by an Ala), the dihydroceramide Δ4-desaturase activity of the myristoylable DES1-Gly was reproducibly and significantly higher. Finally, the activity of wild-type DES1 was also linearly increased in the presence of increased concentrations of Myristic acid incubated with the cells. These results demonstrate that DES1 is a newly discovered myristoylated protein. This N-terminal modification has a great impact on dihydroceramide Δ4-desaturase activity.
    CONCLUSIONS:
    These results suggest therefore that Myristic acid may play an important role in the biosynthesis of ceramide and in sphingolipid metabolism.
    Br J Nutr. 2002 Mar;87(3):199-210.
    Dietary myristic acid modifies the HDL-cholesterol concentration and liver scavenger receptor BI expression in the hamster.[Pubmed: 12064328 ]
    The influence of Myristic acid in a narrow physiological range (0.5 to 2.4% of total dietary energy) on the plasma and hepatic cholesterol metabolism was investigated in the hamster.
    METHODS AND RESULTS:
    The hamsters were fed on a diet containing 12.5 g fat/100 g and 0.05 g cholesterol/100 g with 0.5% Myristic acid (LA diet) for 3 weeks (pre-period). During the following 3 weeks (test period), they were divided into four dietary groups with 0.5% (LA), 1.2% (LM), 1.8% (ML) or 2.4% (M) Myristic acid. Finally, half the hamsters in each group were again fed the LA diet for another 3 weeks (post-period). At the end of the test period, the hepatic expression of the scavenger receptor BI (SR-BI) was lower in the LM, ML and M groups than in the LA group whereas the hepatic cholesteryl ester concentration was higher. Cholesterol 7alpha hydroxylase activity was lower in the ML and M groups than in the LA and LM groups while the sterol 27 hydroxylase and 3-hydroxy-3-methyl glutaryl coenzyme A reductase activities were not modulated by dietary Myristic acid. This is the first time a negative correlation has been observed between the HDL-cholesterol concentration and the hepatic mass of SR-BI (r -0.69; P<0.0001) under physiological conditions. An inverse linear regression was also shown between SR-BI and the percentage of Myristic acid in the diet (r -0.75; P<0.0001). The hepatic mass of SR-BI in the M group had increased at the end of the post-period compared with the test-period values.
    CONCLUSIONS:
    The present investigation shows that Myristic acid modulates HDL-cholesterol via a regulation of the SR-BI expression.
    Nature. 1987 Apr 9-15;326(6113):619-22.
    Myristic acid is coupled to a structural protein of polyoma virus and SV40.[Pubmed: 3031509]
    In the lytic cycle of papova viruses, both uncoating of the viral genome after infection and assembly of functional virions take place in the cell nucleus. The mechanisms by which newly internalized virions are targeted to the nucleus and viral DNA encapsidated into particles are poorly understood. Although the major capsid protein VP1 is involved in endocytosis, and largely defines virion structure, the functions of the minor proteins VP2 and VP3 have remained obscure.
    METHODS AND RESULTS:
    Here we show that VP2 from both polyoma virus and simian virus 40 (SV40) is covalently linked to Myristic acid; this is the first report of a myristylated protein in the nucleus and of a fatty acid being important in the structure of a nonenveloped virus.
    CONCLUSIONS:
    We consider the implications of this unusual modification on encapsidation and suggest that VP2 may be a scaffolding protein for virion assembly.
    Scutellarein-7-O-glucoside

    Catalog No: CFN95082
    CAS No: 26046-94-6
    Price: $318/5mg
    Physalin G

    Catalog No: CFN95104
    CAS No: 76045-38-0
    Price: $388/5mg
    Quercetin 7-O-(6''-O-malonyl)-beta-D-glucoside

    Catalog No: CFN95208
    CAS No: 98767-37-4
    Price: $388/5mg
    Gypenoside XIII

    Catalog No: CFN95239
    CAS No: 80325-22-0
    Price: $288/10mg
    Vanillic acid glucoside

    Catalog No: CFN95257
    CAS No: 32142-31-7
    Price: $318/5mg
    Dioscoreside E

    Catalog No: CFN95346
    CAS No: 435321-73-6
    Price: $318/5mg
    3beta-Hydroxyurs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester

    Catalog No: CFN95461
    CAS No: 434942-42-4
    Price: $318/5mg
    Giganteone A

    Catalog No: CFN95481
    CAS No: 460337-13-7
    Price: $318/5mg
    8-epi-Confertin

    Catalog No: CFN95509
    CAS No: 110115-60-1
    Price: $318/5mg
    Ganosinensic acid C

    Catalog No: CFN95567
    CAS No: 2231756-23-1
    Price: $413/5mg